Narrows FY22 revenue view to $1.557B-$1.558B from $1.551B-$1.563B, consensus $1.56B.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on IART:
- Integra LifeSciences Reports Select Preliminary Fourth Quarter and Full-Year 2022 Financials
- Integra LifeSciences to Present at 41st Annual J.P. Morgan Healthcare Conference
- Integra LifeSciences price target raised to $60 from $50 at Citi
- Integra LifeSciences Completes the Acquisition of Surgical Innovation Associates
- Integra LifeSciences plans $150M share repurchase